Neoadjuvant Cemiplimab in Stage I-II Merkel Cell Carcinoma: Safety and Biomarker Analysis
Condition: Merkel Cell Carcinoma Intervention: Drug: Cemiplimab-Rwlc Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Regeneron Pharmaceuticals; Sanofi-Synthelabo Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Merkel Cell Carcinoma | Neoadjuvant Therapy | Research